RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis

Journal of Neuroimmunology
Christopher G DeVryS Iyer

Abstract

The therapeutic value of a novel immunomodulatory peptide, RDP58, was investigated in the acute experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). RDP58 is a 10-amino acid peptide with two major activities: (i) inhibition of inflammatory TH1 cytokines such as TNFalpha, IFNgamma, and IL12 and (ii) up-regulation of heme oxygenase-1 (HO-1) expression. Experiments in which EAE-induced Lewis rats exhibit an acute monophasic episode of disease demonstrated that a single intracerebroventricular injection of RDP58 is effective in preventing clinical signs of disease. The therapeutic effect on disease activity was observed at all pre-onset administration times and at all doses tested. Consistent with disease activity in vivo, RDP58-treated animals had reduced cellular infiltration within the spinal cord along with decreased TNFalpha expression levels. The data in this proof of concept study support the premise that RDP58, as a platform molecule, may be a promising new therapeutic intervention in autoimmune and inflammatory diseases.

References

Jun 1, 1994·European Journal of Immunology·O RottE Cash
Oct 1, 1995·Clinical Immunology and Immunopathology·R H Swanborg
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·K D Poss, S Tonegawa
Dec 31, 1997·Journal of Neuroimmunology·A H CrossT P Misko
Aug 4, 1998·Journal of Neuroimmunology·A H CrossT P Misko
Aug 14, 1998·Nature Biotechnology·G GrassyR Buelow
Mar 23, 2001·Annals of Neurology·R Hohlfeld, H Wiendl
Sep 7, 2001·Current Opinion in Immunology·L Steinman
Apr 23, 2002·Nature Reviews. Neuroscience·Bernhard HemmerHans-Peter Hartung
Sep 13, 2002·Journal of Neuroimmunology·Stanislava Stosic-GrujicicMarija Mostarica-Stojkovic
Oct 9, 2002·Current Pharmaceutical Design·Suhasini IyerRoland Buelow
Oct 16, 2002·Annals of the Rheumatic Diseases·R BoismenuR Buelow
Jan 24, 2003·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·S MurthyR Buelow
Apr 30, 1935·The Journal of Experimental Medicine·T M Rivers, F F Schwentker

❮ Previous
Next ❯

Citations

Oct 11, 2011·Rheumatology·Fui G Goh, Kim S Midwood
May 14, 2014·Inflammation·Bao-Zhu LiDong-Qing Ye
Nov 3, 2010·Expert Opinion on Biological Therapy·Felix I L Clanchy, Sandra M Sacre
Jun 23, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Ahmed H Badawi, Teruna J Siahaan
Dec 29, 2007·Journal of Autoimmunity·Wujiang LiuYi Luo
Mar 28, 2013·Pharmacology & Therapeutics·Jing LiHang Yin
May 14, 2016·Nature Reviews. Rheumatology·Leo A B JoostenMihai G Netea
Jul 27, 2005·Inflammatory Bowel Diseases·Simon TravisUNKNOWN RDP Investigators Study Group
Mar 7, 2006·Biopolymers·Maria Claudia Alcaro, Anna Maria Papini
Mar 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Krishnakumar Devadas, Subhash Dhawan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here